Amman, May 18 (Petra) -- Regional pharmaceutical leader MS Pharma on Monday announced it has secured a strategic investment from Olayan Financing Company, which acquired a minority stake in the firm to accelerate growth and expansion plans across Saudi Arabia and the Middle East and North Africa (MENA) region.
According to a corporate statement, the transaction involves the issuance of new shares in exchange for a cash injection from Olayan Financing Company. The capital will strengthen MS Pharma's financial and operational capabilities, backing its strategic roadmap to expand its portfolio of generic and biosimilar medicines while scaling up its manufacturing and supply capacity.
The partnership marks a new phase in the company's trajectory, reflecting its commitment to investing in innovation, widening its regional footprint, and creating sustainable, long-term value.
MS Pharma Chairman Ghiath Sukhtian stated that the partnership with Olayan Financing Company represents a qualitative addition for the firm, given the group's extensive investment and operational expertise alongside its deep-rooted presence in the Saudi market. He added that the investment underscores MS Pharma's positioning as a leading regional pharmaceutical corporation.
MS Pharma Chief Executive Officer Kalle Känd noted that the investment arrives at a pivotal juncture in the company's growth. He emphasized that it will bolster the firm's expertise in the biopharmaceutical sector, accelerate its expansion across Saudi Arabia and the wider region, and drive its strategic roadmap within the biosimilars segment.
Nabeel Al Amudi, Chief Executive Officer of Olayan Financing Company, commented that MS Pharma has successfully built a robust pharmaceutical platform in the region with advanced capabilities in generics and biologics. He expressed the group's commitment to supporting MS Pharma's expansion in alignment with Olayan’s long-term investment philosophy.
The statement highlighted MS Pharma's ongoing efforts to reinforce its presence in the biologics sector. Its biopharmaceutical plant in Saudi Arabia has become the first facility in the Kingdom to receive Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority (SFDA) for biologics manufacturing. The company plans to become the first local supplier of domestically manufactured biopharmaceuticals to the Saudi market during the current year.
The pharmaceutical firm confirmed that these milestones support localization targets outlined within Saudi Arabia's National Biotechnology Strategy and Vision 2030, while simultaneously improving access to high-quality biological treatments across the region.
MS Pharma operates as a prominent regional pharmaceutical manufacturer in the MENA market, running five manufacturing facilities across Jordan, Algeria, and Saudi Arabia and employing a workforce of over 2,000 personnel spread across 12 countries.
//Petra// AF
